Scorpius Holdings, Inc. Stock

Equities

HTBX

US42237K4094

Pharmaceuticals

Market Closed - OTC Markets 15:59:59 2024-07-16 EDT 5-day change 1st Jan Change
0.0284 USD +3.59% Intraday chart for Scorpius Holdings, Inc. +13.60% -93.55%
Sales 2022 6.38M 8.73M Sales 2023 6.99M 9.56M Capitalization 11.48M 15.7M
Net income 2022 -43M -58.79M Net income 2023 -45M -61.52M EV / Sales 2022 -2.23 x
Net cash position 2022 34.88M 47.69M Net Debt 2023 11.65M 15.93M EV / Sales 2023 3.31 x
P/E ratio 2022
-0.47 x
P/E ratio 2023
-0.25 x
Employees 83
Yield 2022 *
-
Yield 2023
-
Free-Float 96.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.59%
1 week+13.60%
Current month-6.27%
1 month-62.78%
3 months-82.08%
6 months-92.72%
Current year-93.55%
More quotes
1 week
0.02
Extreme 0.0211
0.03
1 month
0.02
Extreme 0.021
0.05
Current year
0.02
Extreme 0.015
0.53
1 year
0.02
Extreme 0.015
0.74
3 years
0.02
Extreme 0.015
7.63
5 years
0.02
Extreme 0.015
30.10
10 years
0.02
Extreme 0.015
763.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 08-06-09
Director of Finance/CFO 56 19-09-24
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 70 16-04-25
Chief Executive Officer 60 08-06-09
Director/Board Member 48 08-12-31
More insiders
Date Price Change Volume
24-07-16 0.0284 +3.59% 491,374
24-07-15 0.0275 +5.62% 480,686
24-07-12 0.026 +13.04% 279,846
24-07-11 0.023 +9.00% 731,104
24-07-10 0.0211 -15.60% 643,881

Delayed Quote OTC Markets, July 16, 2024 at 03:59 pm

More quotes
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
More about the company